Novo Nordisk A S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Ticker
- NVO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- 52-week range
- $35.12 - $64.16
Valuation
- Share price
- $41.60 (close of Nov 16, 2026)
- P/E (TTM)
- 11.09x
- Price to book
- 5.74x
- Price to free cash flow
- 17.43x
Price performance
| Period | Change |
|---|---|
| 1 day | -0.07% |
| 5 days | +0.53% |
| 1 month | +7.13% |
| 3 months | -9.35% |
| 6 months | -7.02% |
| Year to date | -18.24% |
| 1 year | -13.80% |
| 3 years | -58.20% |
| 5 years | -27.01% |
| 10 years | +152.88% |
| All time | +25,900.00% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 1.21%
- Shares short
- 38.29M
- Days to cover
- 4.04
- Change since prior report
- +2.27%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed NVO trades
Lisa McClain · Scott Franklin · Marjorie Taylor Greene · Byron Donalds · Kevin Hern · Alan Armstrong · Laurel Lee · Val Hoyle
Super investors holding NVO
Dodge & Cox (Dodge & Cox Funds) · Sarah Ketterer (Causeway Capital Management LLC) · Lee Ainslie (Maverick Capital LTD) · Ken Griffin (Citadel)
Profitability and growth
- Return on equity
- 52.79%
- Return on invested capital
- 30.63%
- Return on assets
- 18.87%
- Return on capital employed
- 39.01%
- Gross margin
- 80.98%
- Net margin
- 33.14%
- EBITDA margin
- 46.05%
- Revenue growth
- 6.43%
- Net income growth
- 1.43%
- Free cash flow growth
- -20.11%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.74%
- Current ratio
- 0.84x
- Net debt to EBITDA
- 0.54x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Shares outstanding
- 4.44B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 80.98% | 33.14% | 52.79% | 30.63% |
| 2024-12-31 | 84.67% | 34.78% | 70.38% | 41.47% |
| 2023-12-31 | 84.60% | 36.03% | 78.53% | 61.08% |
| 2022-12-31 | 83.92% | 31.38% | 66.51% | 56.07% |
| 2021-12-31 | 83.20% | 33.92% | 67.50% | 46.61% |
| 2020-12-31 | 83.51% | 33.19% | 66.54% | 55.76% |
| 2019-12-31 | 83.54% | 31.92% | 67.63% | - |
| 2018-12-31 | 84.25% | 34.54% | 74.52% | - |
| 2017-12-31 | 84.21% | 34.14% | - | - |
| 2016-12-31 | 84.63% | 33.93% | - | - |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-04 | Sep 2026 | - |
| 2026-08-04 | Jun 2026 | - |
| 2026-05-06 | Mar 2026 | - |
| 2026-02-04 | Dec 2025 | - |
| 2025-11-05 | Sep 2025 | - |
| 2025-08-06 | Jun 2025 | - |
| 2025-05-07 | Mar 2025 | - |
| 2025-02-05 | Dec 2024 | - |
Filings and sources
- Company website
- novonordisk.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
GSK plc (GSK) · Organon & Co. (OGN) · Biogen Inc. (BIIB) · Bristol Myers Squibb Co (BMY) · Pfizer Inc (PFE) · Gilead Sciences, Inc. (GILD) · Amgen Inc (AMGN) · AstraZeneca plc (AZN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades